financetom
Business
financetom
/
Business
/
Israeli identity and security solutions firm SuperCom's Q3 revenue beats expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Israeli identity and security solutions firm SuperCom's Q3 revenue beats expectations
Nov 13, 2025 6:47 AM

Overview

* SuperCom ( SPCB ) Q3 revenue beats analyst expectations, despite a year-over-year decline

* Company secured over 30 new EM contracts in the U.S. since mid-2024

Outlook

* SuperCom ( SPCB ) did not provide specific financial guidance for future quarters or the full year

Result Drivers

* GROSS MARGIN EXPANSION - Co achieved higher gross margins, expanding to 60.8% from 45.6%, contributing to improved profitability

* NEW CONTRACTS - SuperCom ( SPCB ) secured over 30 new electronic monitoring contracts in the U.S., boosting market presence and revenue

* DISPLACING INCUMBENTS - Co's ability to replace legacy vendors in new markets, including Germany, contributed to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $6.22 $5.76

Revenue mln mln (2

Analysts

)

Q3 Beat $0.39 -$0.12

Adjusted (2

EPS Analysts

)

Q3 Net $691,000

Income

Q3 EBIT $639,000

Q3 $2.20

EBITDA mln

Q3 Gross $3.78

Profit mln

Q3 $3.14

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Supercom Ltd ( SPCB ) is $15.00, about 33% above its November 12 closing price of $10.05

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trump Media & Technology Launches Truth+ Streaming Service
Trump Media & Technology Launches Truth+ Streaming Service
Oct 17, 2024
09:06 AM EDT, 10/14/2024 (MT Newswires) -- Trump Media & Technology Group ( DJT ) said Monday that it launched its Truth+ TV streaming service at player.truthsocial.tv. Truth Social account holders can now access a full range of streaming content, while non-account holders can sign up on the site, the company said. Truth+ is already available as an Android app,...
High Flood Scores Recorded For Multiple Municipal Bond Offerings This Week
High Flood Scores Recorded For Multiple Municipal Bond Offerings This Week
Oct 17, 2024
09:06 AM EDT, 10/14/2024 (MT Newswires) -- Multiple municipal bond offerings this week have a high exposure to climate risk, specifically high Flood Scores, according to ICE Climate Data. An $11 million offering from Point Pleasant, N.J., records a Flood Score of 4.9 out of 5.0, ICE reports. Locations with a component Physical Climate Risk Score, which includes Flood, Wildfire...
EU tariffs on Chinese EVs to accelerate plant closures in Europe, Tavares says
EU tariffs on Chinese EVs to accelerate plant closures in Europe, Tavares says
Oct 17, 2024
PARIS, Oct 14 (Reuters) - The European Union's duties on Chinese electric cars (EVs) will accelerate plant closures in Europe by local automakers, as tariffs will push Chinese manufacturers to build facilities in Europe, exacerbating overcapacity problems, Stellantis ( STLA ) CEO said on Monday. Tariffs are a good communication tool but have side effects, Carlos Tavares said during the...
Exelixis, Merck Partner for Trials of Cancer Combination Therapies
Exelixis, Merck Partner for Trials of Cancer Combination Therapies
Oct 17, 2024
09:02 AM EDT, 10/14/2024 (MT Newswires) -- Exelixis ( EXEL ) and Merck ( MRK ) said Monday they have signed a clinical development collaboration for trials of combination therapies for head and neck cancer and renal cell carcinoma, a type of kidney cancer. Under the terms of the collaboration, the companies said they will evaluate Exelixis' ( EXEL )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved